Increasing prevalence of chronic diseases is expected to drive the growth of global vulvovaginal candidiasis treatment in the forecast period, 2024-2028.
According to TechSci Research report, “Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”, the global dental contouring market is anticipated to grow at an impressive rate in the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of diabetes cases and increasing unrestrained usage of antibiotics leading to high prevalence of yeast infection among individuals across the globe. Additionally, increasing demand for better treatment and the rising burden of different chronic diseases like neurological disorder, and cancer, especially in the developed countries in the North America and Europe, are expected to create lucrative opportunities for market growth in the coming years. Besides, increasing research and development activities in healthcare industry is further expected to support the market growth. Similarly, growing approval of newly developed antifungal drugs and increasing the number of market players are expected to boost market growth during the forecast period. Also, growing awareness about new drugs for the treatment of fungal diseases and growing demand for advanced therapeutic options will drive the market growth over the years.
However, increasing resistance for antifungal drugs among the population is slowing down the growth of global vulvovaginal candidiasis treatment market in the forecast period. Similarly, high risks and complications associated with drugs such as the incidence of miscarriage due to fluconazole and treatments may hamper the vulvovaginal candidiasis treatment market growth during the forecast period. Also, the lack of awareness about maintaining good hygiene among the female population, in emerging countries, can further restrict the growth of the global vulvovaginal candidiasis treatment market.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Vulvovaginal Candidiasis Treatment Market"
The global vulvovaginal candidiasis treatment market can be segmented by drug class, by route of administration, by distribution channel and by region.
Based on drug class, the global vulvovaginal candidiasis treatment market can be segmented into Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others. The clotrimazole segment dominated the market in 2022 and is expected to continue maintaining its dominance throughout the forecast period. This can be ascribed to high efficiency and increasing usage of clotrimazole drug for the treatment of acute vulvovaginal candidiasis disease.
Based on route of administration, the market can be segmented into Oral, Intravenous, Topical. The oral segment is expected to dominate during the forecast period on account of the fact that most of the acute vulvovaginal candidiasis treatment drugs are taken orally and increasing the large patient pools in the hospitals. Similarly, the increasing demand for prescription products because of growing moderate to severe disease cases will further propel the market growth over the years.
Major companies operating in global vulvovaginal candidiasis treatment market are:
- Astellas Pharma Inc.
- Mycovia Pharmaceuticals, Inc.
- Basilea Pharmaceutica Ltd.
- Scynexis, Inc.
- Grupo Ferrer Internacional, S.A.
- Pfizer, Inc.
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc.
- Cidara Therapeutics, Inc.
- Amplyx Pharmaceuticals Inc.
For instance, on August 26, 2020, Mycovia Pharmaceuticals, Inc. published positive results for the Phase II clinical trials, which was conducted for testing the safety and efficacy of their oral drug candidate oteseconazole (VT-1161), an antifungal drug, for the treatment of vulvovaginal candidiasis.
For instance, on April 29, 2020, researchers at the University of Bristol, U.K. found that C12AHL, a chemical released from the bacterial species Pseudomonas aeruginosa, acts as the chemical signal for Candida species.
Customers can also request for 10% free customization on this report.
“North America is expected to dominate in the global vulvovaginal candidiasis treatment market due to the developed reimbursement procedures for the diagnosis and testing of vaginal fungal infection. Similarly, increasing the number of hospital-acquired infections is expected to propel the growth of the market over the years. Furthermore, the increasing prevalence of vaginal fungal infections among the population and major key players investing in the research and development sector for developing new drugs for the treatment is further contributing to the demand for vulvovaginal candidiasis treatment. Also, the presence of other tropical products the counter and prescription formulations will drive the market growth during the forecasted period. Besides, the availability of skilled professionals and early adoption of advanced treatments for the treatment of different vulvovaginal candidiasis infections in the region, are further expected to create lucrative opportunities for the market growth” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others), By Route of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition”, has evaluated the future growth potential of global vulvovaginal candidiasis treatment market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global vulvovaginal candidiasis treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com
The latest trending report Global Drugs for Vulvovaginal Candidiasis Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.
The report will assist reader with better understanding and decision making.The Drugs for Vulvovaginal Candidiasis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.This report also researches and evaluates the impact of Covid-19 outbreak on the Drugs for Vulvovaginal Candidiasis industry, involving potential opportunity and challenges, drivers and risks.
We present the impact assessment of Covid-19 effects on Drugs for Vulvovaginal Candidiasis and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.
).Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/24609-drugs-for-vulvovaginal-candidiasis-market-analysis-reportThe major players covered in Drugs for Vulvovaginal Candidiasis are:BayerSanofiPfizerPerrigoTevaJ & JKingyork GroupEffikBristol-Myers SquibbCisen PharmaceuticalBy Type, Drugs for Vulvovaginal Candidiasis market has been segmented into:MiconazoleClotrimazoleFluconazoleEconazoleOtherBy Application, Drugs for Vulvovaginal Candidiasis has been segmented into:Hospital & ClinicPharmacyThe report offers in-depth assessment of the growth and other aspects of the Drugs for Vulvovaginal Candidiasis market in important countries (regions), including:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, etc.
)Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Drugs for Vulvovaginal Candidiasis Market @ https://www.decisiondatabases.com/contact/download-sample-24609The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Drugs for Vulvovaginal Candidiasis product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Drugs for Vulvovaginal Candidiasis, with price, sales, revenue and global market share of Drugs for Vulvovaginal Candidiasis in 2018 and 2019.Chapter 3, the Drugs for Vulvovaginal Candidiasis competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Drugs for Vulvovaginal Candidiasis breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Drugs for Vulvovaginal Candidiasis Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-24609All Drugs Related Reports by DecisionDatabases.com @ https://goo.gl/knWRNbAbout-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.
Global Candidiasis Treatment Market: OverviewCandida yeasts generally live within the intestinal tract, and they are also found on mucous membranes and the skin.
Candidiasis is a fungal infection caused by Candida sp.
The diagnosis of candidiasis depends on the medical history of the patient, symptoms, physical investigations, laboratory examinations, and others.
When laboratory tests find growth of Candida yeasts in the cultured blood, medical practitioners treat candidiasis by prescribing a specific dose of antifungal medications.
However, the treatment of candidiasis depend on the age of patients, symptoms, medical history, immunity status, location of the infections, etc.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=62736Global Candidiasis Treatment Market: Key TrendsThe global candidiasis treatment market is primarily driven by a rise in the cases of candidiasis worldwide and high rate of diagnosis and treatment of candidiasis.
In terms of distribution channel, the global candidiasis treatment market can be segmented into hospital pharmacies, retail pharmacies and drug stores, and online sales.Request COVID Analysis on Candidiasis Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=62736 Global Candidiasis Treatment Market: Regional AnalysisBased on geography, the global candidiasis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
